Related Experiment Video
Updated: Jan 12, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Emerging neuromodulation treatments for opioid and stimulant use disorders
Susanna D Howard1, Liming Qiu1, Nathan Hager2
1Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, United States.
Abstract:
Over the past decade, deaths attributable to opioid and stimulant use have risen dramatically. While the U.S. Food and Drug Administration (FDA) has approved three medications for opioid use disorder, there is currently no FDA-approved treatment for stimulant use disorder. Despite the availability of medications for opioid use disorder, the rates of relapse and overdose, particularly in the time of widespread fentanyl use, remain distressingly high. There is an urgent need for more effective treatment options for these debilitating disorders. This article provides an overview of the current standard of care for opioid use disorder and stimulant use disorder. New and emerging neuromodulation approaches with a particular focus on deep brain stimulation are then discussed.
Related Concept Videos
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Drug Abuse and Addiction: Pharmacological Phenomena
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Antidepressant Drugs: MAOIs and Other Agents

